UTHR RSI Chart
Last 7 days
13.7%
Last 30 days
14.0%
Last 90 days
26.4%
Trailing 12 Months
26.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 2.5B | 0 | 0 | 0 |
2023 | 2.0B | 2.1B | 2.2B | 2.3B |
2022 | 1.8B | 1.8B | 1.9B | 1.9B |
2021 | 1.5B | 1.6B | 1.7B | 1.7B |
2020 | 1.4B | 1.4B | 1.4B | 1.5B |
2019 | 1.6B | 1.5B | 1.5B | 1.4B |
2018 | 1.7B | 1.7B | 1.7B | 1.6B |
2017 | 1.6B | 1.6B | 1.7B | 1.7B |
2016 | 1.5B | 1.6B | 1.6B | 1.6B |
2015 | 1.3B | 1.3B | 1.4B | 1.5B |
2014 | 1.2B | 1.2B | 1.2B | 1.3B |
2013 | 957.0M | 1.0B | 1.1B | 1.1B |
2012 | 784.9M | 826.7M | 867.4M | 916.1M |
2011 | 629.5M | 678.5M | 711.7M | 743.2M |
2010 | 405.1M | 455.8M | 527.2M | 592.9M |
2009 | 0 | 307.3M | 333.1M | 358.9M |
2008 | 0 | 0 | 0 | 281.5M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 06, 2024 | rothblatt martine a | acquired | 466,164 | 129 | 3,600 | chairperson & ceo |
May 06, 2024 | benkowitz michael | acquired | 5,258,260 | 163 | 32,200 | president and coo |
May 06, 2024 | benkowitz michael | back to issuer | -8,388,420 | 260 | -32,200 | president and coo |
May 06, 2024 | rothblatt martine a | sold | -934,929 | 259 | -3,600 | chairperson & ceo |
May 03, 2024 | causey christopher | acquired | 251,194 | 112 | 2,240 | - |
May 03, 2024 | causey christopher | sold | -582,195 | 259 | -2,240 | - |
May 03, 2024 | rothblatt martine a | sold | -936,304 | 260 | -3,600 | chairperson & ceo |
May 03, 2024 | olian judy d. | sold | -2,585,600 | 258 | -10,000 | - |
May 03, 2024 | sullivan louis w | acquired | 617,962 | 119 | 5,160 | - |
May 03, 2024 | sullivan louis w | sold | -1,333,280 | 258 | -5,160 | - |
Which funds bought or sold UTHR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 06, 2024 | Advisory Services Network, LLC | sold off | -100 | -46,177 | - | -% |
May 06, 2024 | TEXAS PERMANENT SCHOOL FUND CORP | added | 1.45 | 533,154 | 9,448,150 | 0.07% |
May 06, 2024 | Empowered Funds, LLC | added | 84.08 | 4,604,430 | 9,592,420 | 0.17% |
May 06, 2024 | JOHN G ULLMAN & ASSOCIATES INC | reduced | -15.12 | -227,266 | 1,780,330 | 0.27% |
May 06, 2024 | Savant Capital, LLC | new | - | 2,265,500 | 2,265,500 | 0.03% |
May 06, 2024 | DiNuzzo Private Wealth, Inc. | unchanged | - | 99.00 | 2,298 | -% |
May 06, 2024 | Parallel Advisors, LLC | added | 8.63 | 21,648 | 182,168 | -% |
May 06, 2024 | Metis Global Partners, LLC | reduced | -1.6 | 10,342 | 380,417 | 0.01% |
May 06, 2024 | Roundview Capital LLC | sold off | -100 | -741,250 | - | -% |
May 06, 2024 | Addison Advisors LLC | unchanged | - | 737 | 17,229 | 0.01% |
Unveiling United Therapeutics Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to United Therapeutics Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.4B | 6.8B | -7.77 | 6.77 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.5B | 2.0B | -58.76 | 9.74 | ||||
BMRN | 15.7B | 2.5B | 76.35 | 6.35 | ||||
INCY | 12.2B | 3.8B | 16.38 | 3.24 | ||||
MID-CAP | ||||||||
APLS | 5.3B | 524.1M | -12.77 | 10.17 | ||||
BBIO | 5.2B | 107.9M | -9.51 | 48.09 | ||||
AXSM | 3.7B | 251.0M | -12.33 | 14.56 | ||||
ARWR | 3.1B | 240.7M | -10.44 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -46.38 | 3.91 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.99 | 4.48 | ||||
NVAX | 645.2M | 983.7M | -1.18 | 0.66 | ||||
CRBP | 424.2M | 881.7K | -12.56 | 481.06 | ||||
INO | 259.6M | 4.9M | -1.92 | 53.35 | ||||
IBIO | 7.1M | 2.1M | -0.26 | 2.14 |
United Therapeutics Corp News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 10.2% | 678 | 615 | 609 | 597 | 507 | 492 | 516 | 467 | 462 | 415 | 445 | 447 | 379 | 385 | 380 | 362 | 356 | 311 | 402 | 374 | 363 |
Costs and Expenses | -9.4% | 321 | 355 | 282 | 283 | 223 | 316 | 202 | 265 | 174 | 245 | 216 | 224 | 444 | 320 | 159 | 222 | 190 | 248 | 218 | 152 | 1,019 |
S&GA Expenses | 9.2% | 144 | 132 | 128 | 130 | 87.00 | 163 | 98.00 | 142 | 79.00 | 128 | 109 | 113 | - | - | - | - | - | - | - | - | - |
R&D Expenses | -31.2% | 104 | 151 | 85.00 | 89.00 | 83.00 | 94.00 | 66.00 | 94.00 | 69.00 | 83.00 | 79.00 | 74.00 | 304 | 126 | 69.00 | 90.00 | 73.00 | 114 | 86.00 | 86.00 | 897 |
EBITDA Margin | 0.4% | 0.60* | 0.60* | 0.57* | 0.58* | 0.52* | 0.53* | 0.53* | 0.49* | 0.53* | 0.39* | 0.38* | 0.41* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -11.9% | 13.00 | 15.00 | 16.00 | 15.00 | 14.00 | 12.00 | 9.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 8.00 | 10.00 | 12.00 | 12.00 | 10.00 |
Income Taxes | 17.5% | 92.00 | 78.00 | 84.00 | 76.00 | 51.00 | 47.00 | 73.00 | 35.00 | 69.00 | 28.00 | 42.00 | 44.00 | 4.00 | 16.00 | 48.00 | 27.00 | 34.00 | 16.00 | 35.00 | 45.00 | -156 |
Earnings Before Taxes | 34.9% | 399 | 295 | 352 | 335 | 292 | 179 | 313 | 151 | 309 | 141 | 204 | 217 | 33.00 | 114 | 219 | 134 | 172 | 68.00 | 167 | 250 | -650 |
EBT Margin | 1.0% | 0.55* | 0.55* | 0.53* | 0.53* | 0.47* | 0.49* | 0.49* | 0.45* | 0.49* | 0.35* | 0.34* | 0.37* | - | - | - | - | - | - | - | - | - |
Net Income | 41.2% | 307 | 217 | 268 | 259 | 241 | 132 | 239 | 116 | 240 | 112 | 163 | 173 | 28.00 | 99.00 | 171 | 107 | 138 | 53.00 | 132 | 205 | -494 |
Net Income Margin | -0.6% | 0.42* | 0.42* | 0.41* | 0.41* | 0.37* | 0.38* | 0.38* | 0.35* | 0.39* | 0.28* | 0.28* | 0.30* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 369.9% | 338 | 72.00 | 281 | 62.00 | 334 | 89.00 | 190 | 110 | 275 | 104 | 162 | 132 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -9.4% | 6,495 | 7,167 | 7,024 | 6,681 | 6,346 | 6,045 | 5,782 | 5,543 | 5,360 | 5,169 | 5,049 | 4,845 | 4,641 | 4,615 | 4,411 | 4,219 | 4,026 | 3,913 | 4,000 | 3,899 | 3,727 |
Current Assets | -8.5% | 3,249 | 3,551 | 3,459 | 3,213 | 3,193 | 3,380 | 3,056 | 2,684 | 2,587 | 2,324 | 2,386 | 2,318 | 2,014 | 2,167 | 1,868 | 1,894 | 1,846 | 1,865 | 1,933 | 2,140 | 1,943 |
Cash Equivalents | 3.6% | 1,252 | 1,208 | 1,108 | 1,067 | 1,164 | 961 | 967 | 795 | 813 | 895 | 909 | 942 | 832 | 739 | 670 | 685 | 875 | 738 | 720 | 881 | 791 |
Inventory | 7.5% | 120 | 112 | 104 | 103 | 103 | 102 | 91.00 | 90.00 | 88.00 | 94.00 | 97.00 | 90.00 | 92.00 | 87.00 | 88.00 | 90.00 | 92.00 | 93.00 | 94.00 | 97.00 | 96.00 |
Net PPE | 2.7% | 1,074 | 1,045 | 992 | 939 | 897 | 862 | 841 | 791 | 784 | 781 | 727 | 716 | 714 | 732 | 736 | 744 | 739 | 739 | 678 | 709 | 701 |
Liabilities | -2.1% | 1,157 | 1,182 | 1,312 | 1,270 | 1,223 | 1,248 | 1,219 | 1,225 | 1,184 | 1,210 | 1,219 | 1,205 | 1,196 | 1,220 | 1,128 | 1,126 | 1,077 | 1,133 | 1,284 | 1,332 | 1,389 |
Current Liabilities | 7.0% | 861 | 804 | 744 | 370 | 325 | 343 | 316 | 332 | 293 | 305 | 320 | 311 | 302 | 323 | 259 | 255 | 207 | 463 | 470 | 464 | 270 |
Shareholder's Equity | -10.8% | 5,338 | 5,985 | 5,712 | 5,411 | 5,123 | 4,797 | 4,562 | 4,318 | 4,176 | 3,959 | 3,830 | 3,640 | 3,445 | 3,395 | 3,283 | 3,094 | 2,949 | 2,780 | 2,716 | 2,558 | 2,319 |
Retained Earnings | 5.1% | 6,334 | 6,027 | 5,810 | 5,542 | 5,283 | 5,042 | 4,910 | 4,671 | 4,555 | 4,315 | 4,203 | 4,040 | 3,868 | 3,839 | 3,740 | 3,569 | 3,462 | 3,325 | 3,273 | 3,140 | 2,935 |
Additional Paid-In Capital | -5.6% | 2,405 | 2,549 | 2,524 | 2,498 | 2,457 | 2,388 | 2,315 | 2,292 | 2,254 | 2,245 | 2,226 | 2,197 | 2,173 | 2,149 | 2,126 | 2,105 | 2,068 | 2,048 | 2,026 | 2,002 | 1,968 |
Shares Outstanding | -6.0% | 44.00 | 47.00 | 47.00 | 47.00 | 47.00 | 46.00 | 46.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 9,138 | - | - | - | 10,532 | - | - | - | 7,912 | - | - | - | 4,726 | - | - | - | 2,977 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 149.8% | 376,500 | 150,700 | 346,200 | 106,300 | 374,800 | 128,200 | 258,600 | 127,000 | 288,700 | 174,600 | 185,600 | 148,200 | 89,800 | 126,200 | 250,900 | 164,000 | 214,600 | 102,500 | 185,400 | 132,900 | -627,400 |
Share Based Compensation | 54.2% | 25,600 | 16,600 | 21,100 | 13,800 | -12,400 | 64,800 | -2,400 | 65,500 | -21,100 | 44,700 | 24,600 | 29,100 | 40,100 | 93,700 | -12,500 | 51,800 | 30,800 | 29,500 | 23,900 | -37,200 | 29,200 |
Cashflow From Investing | 1646.6% | 735,300 | 42,100 | -313,400 | -227,200 | -221,100 | -189,300 | -94,000 | -169,000 | -359,200 | -195,800 | -235,900 | -48,900 | -6,300 | -63,800 | -271,700 | -375,400 | -27,600 | 66,200 | -298,700 | -42,600 | -60,300 |
Cashflow From Financing | -1050.9% | -1,068,000 | -92,800 | 7,600 | 24,700 | 48,600 | 55,500 | 7,000 | 23,900 | -11,000 | 7,500 | 16,600 | 10,600 | 10,100 | 6,100 | 5,600 | 21,600 | -50,200 | -150,000 | -48,300 | 400 | 809,100 |
Buy Backs | - | 1,000,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Total revenues | $ 677.7 | $ 506.9 |
Operating expenses: | ||
Cost of sales | 72.9 | 52.3 |
Research and development | 104.1 | 82.9 |
Selling, general, and administrative | 144.4 | 87.3 |
Total operating expenses | 321.4 | 222.5 |
Operating income | 356.3 | 284.4 |
Interest income | 53.8 | 29.2 |
Interest expense | (13.3) | (13.8) |
Other income (expense), net | 1.8 | (7.9) |
Total other income, net | 42.3 | 7.5 |
Income before income taxes | 398.6 | 291.9 |
Income tax expense | (92.0) | (51.0) |
Net income | $ 306.6 | $ 240.9 |
Net income per common share: | ||
Basic (in dollars per share) | $ 6.52 | $ 5.20 |
Diluted (in dollars per share) | $ 6.17 | $ 4.86 |
Weighted average number of common shares outstanding: | ||
Basic (in shares) | 47.0 | 46.3 |
Diluted (in shares) | 49.7 | 49.6 |
Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,251.5 | $ 1,207.7 |
Marketable investments | 1,456.3 | 1,786.4 |
Accounts receivable, no allowance for 2024 and 2023 | 307.3 | 278.9 |
Inventories, net | 120.2 | 111.8 |
Other current assets | 113.4 | 166.2 |
Total current assets | 3,248.7 | 3,551.0 |
Marketable investments | 1,491.9 | 1,909.8 |
Goodwill and other intangible assets, net | 115.4 | 114.2 |
Property, plant, and equipment, net | 1,074.0 | 1,045.4 |
Deferred tax assets, net | 396.1 | 394.8 |
Other non-current assets | 169.1 | 151.8 |
Total assets | 6,495.2 | 7,167.0 |
Current liabilities: | ||
Accounts payable and accrued expenses | 305.1 | 298.0 |
Line of credit (current) | 400.0 | 400.0 |
Share tracking awards plan | 29.2 | 35.4 |
Other current liabilities | 126.3 | 71.0 |
Total current liabilities | 860.6 | 804.4 |
Line of credit (non-current) | 200.0 | 300.0 |
Other non-current liabilities | 96.5 | 77.8 |
Total liabilities | 1,157.1 | 1,182.2 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued | 0.0 | 0.0 |
Common stock, par value $.01, 245,000,000 shares authorized, 74,098,932 and 73,659,761 shares issued, and 44,204,517 and 47,040,545 shares outstanding as of March 31, 2024 and December 31, 2023, respectively | 0.7 | 0.7 |
Additional paid-in capital | 2,405.4 | 2,549.0 |
Accumulated other comprehensive loss | (15.6) | (12.8) |
Treasury stock, 29,894,415 and $26,619,216 shares as of March 31, 2024 and December 31, 2023, respectively | (3,386.1) | (2,579.2) |
Retained earnings | 6,333.7 | 6,027.1 |
Total stockholders’ equity | 5,338.1 | 5,984.8 |
Total liabilities and stockholders’ equity | $ 6,495.2 | $ 7,167.0 |